9,10-dihydro-5-methyl-9-oxo-4-acridinecarboxylic acid | 24782-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9,10-dihydro-5-methyl-9-oxo-4-acridinecarboxylic acid
• 英文别名: 4-methyl-9-oxoacridan-5-carboxylic acid；9-Oxo-5-methylacridon-4-carbonsaeure；4-Methyl-9(10H)acridone-5-carboxylic acid；5-methylacridin-9-one-4-carboxylic acid；5-methyl-9-oxoacridan-4-carboxylic acid；5-Methyl-9-oxo-9,10-dihydroacridine-4-carboxylic acid；5-methyl-9-oxo-10H-acridine-4-carboxylic acid
• CAS: 24782-66-9
• 化学式: C₁₅H₁₁NO₃
• 分子量: 253.257
• InChiKey: ZBJTUFBBPAZNCZ-UHFFFAOYSA-N

物化性质

• 熔点：
  358-368 °C
• 沸点：
  481.6±45.0 °C(Predicted)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  9,10-dihydro-5-methyl-9-oxo-4-acridinecarboxylic acid 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 9-chloro-4-methylacridine-5-dimethylaminoethylcarboxamide
  参考文献：
  名称：

  Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide

  摘要：

  A series of monosubstituted derivatives of the new antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide has been prepared, bearing methyl, methoxy, and chloro groups at available acridine positions. The physicochemical properties and antitumor activity of these compounds varied more with the position than with the nature of the substituent groups. The highest levels of both in vitro and in vivo antileukemic activity were shown by 5-substituted derivatives, while 7- and 8-substituted derivatives possessed the highest selectivity toward the HCT-8 human colon carcinoma line compared to the L1210 mouse leukemia line in vitro.

  DOI：

  10.1021/jm00154a008
• 作为产物：
  描述：

  2-碘异酞酸 在 N-乙基吗啉 、 PPA 、 copper(l) chloride 作用下， 以 苯 为溶剂， 反应 2.0h， 生成 9,10-dihydro-5-methyl-9-oxo-4-acridinecarboxylic acid
  参考文献：
  名称：

  Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide

  摘要：

  A series of monosubstituted derivatives of the new antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide has been prepared, bearing methyl, methoxy, and chloro groups at available acridine positions. The physicochemical properties and antitumor activity of these compounds varied more with the position than with the nature of the substituent groups. The highest levels of both in vitro and in vivo antileukemic activity were shown by 5-substituted derivatives, while 7- and 8-substituted derivatives possessed the highest selectivity toward the HCT-8 human colon carcinoma line compared to the L1210 mouse leukemia line in vitro.

  DOI：

  10.1021/jm00154a008

文献信息

• 5-(9-ACRIDINYLAMINO)-TOLUIDINE COMPOUNDS
  申请人：——

  公开号：US20040198765A1

  公开（公告）日：2004-10-07

  This invention relates to 9-anilinoacridine compounds, and more particularly to their synthesis and their use in pharmaceutical compositions for treating diseases.

  这项发明涉及9-苯胺基吖啶化合物，更具体地涉及它们的合成以及它们在制备治疗疾病的药物组合物中的应用。
• Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine
  作者：William A. Denny、Graham J. Atwell、Bruce C. Baguley

  DOI：10.1021/jm00369a021

  日期：1984.3

  5-disubstituted derivatives all showed high activity when administered ip against ip-implanted P-388, but activity varied widely when the compounds were given orally. 4-Methoxy and 4-carbamoyl derivatives proved essentially inactive, whereas 4-methyl and 4-methylcarbamoyl derivatives retained activity. Exceptional oral activity was shown by the 4-methyl-5-methylcarbamoyl derivative, making this amsacrine

  DNA嵌入剂amsacrine是治疗人类白血病和淋巴瘤的有效药物，但实体瘤活性极低。作为鉴定具有更广谱活性的类似物的第一步，对通过口服（po）和腹膜内（ip）途径给予的Amsacrine类似物的体内抗白血病（P-388）活性进行了比较。一系列的4-取代和4,5-二取代的衍生物在ip注射时对ip植入的P-388均显示出高活性，但是当口服给予化合物时，活性变化很大。事实证明4-甲氧基和4-氨基甲酰基衍生物基本上没有活性，而4-甲基和4-甲基氨基甲酰基衍生物保持活性。4-甲基-5-甲基氨基甲酰基衍生物显示出非凡的口服活性，使该氨溴萘衍生物值得进一步测试。
• 9-anilinoacridine alkylating agents
  申请人：Su Tsann-Long

  公开号：US20080176889A1

  公开（公告）日：2008-07-24

  This invention relates to 9-anilinoacridine alkylating agents, their synthesis and their use in pharmaceutical compositions for treating diseases.

  这项发明涉及9-苯胺基吖啶烷基化剂，它们的合成以及它们在治疗疾病的药物组合物中的应用。
• Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
  作者：Graham J. Atwell、Gordon W. Rewcastle、Bruce C. Baguley、William A. Denny

  DOI：10.1021/jm00387a014

  日期：1987.4

  antileukemic activity, with substituents at nearly all acridine positions proving acceptable. The compounds also show remarkable activity against the Lewis lung solid tumor in vivo, with several analogues capable of effecting 100% cures of the advanced disease. The broad SAR and high solid-tumor activity of the 9-acridine-4-carboxamides imply they should be considered as a completely new class of antitumor

  报道了一系列N- [2-（二烷基氨基）烷基] ac啶-4-羧酰胺的合成，理化性质和抗肿瘤活性。这些化合物通过插层与DNA结合，但由于弱碱性a啶发色团（pKa = 3.5-4.5）而在生理条件下以单阳离子形式存在。an啶-4-甲酰胺显示出非常广泛的抗白血病活性的结构-活性关系（SAR），几乎所有all啶位置上的取代基都被证明是可以接受的。所述化合物还具有体内抗路易斯肺实体瘤的显着活性，其几种类似物能够100％治愈晚期疾病。9-ac啶-4-羧酰胺具有宽泛的SAR和较高的固体肿瘤活性，这意味着它们应被视为一类全新的抗肿瘤药物。
• Anticancer anilinoacridines. A process synthesis of the disubstituted amsacrine analog CI-921
  作者：Sean T. Brennan、Norman L. Colbry、Robert L. Leeds、Boguslawa Leja、Stephen R. Priebe、Michael D. Reily、H. D. Hollis Showalter、Susan E. Uhlendorf、Graham J. Atwell、William A. Denny

  DOI：10.1002/jhet.5570260542

  日期：1989.9

  An improved process for the synthesis of bulk quantities of the clinical amsacrine analog CI-921 is reported. Described also are detailed analytical and spectroscopic data for this agent.

  报道了一种改进的合成大量临床氨苄青霉素类似物CI-921的方法。还描述了该试剂的详细分析和光谱数据。